Literature DB >> 34289701

The potential of miR-499 plasmatic level as a biomarker of obstructive sleep apnea syndrome.

David Slouka1, Jindra Windrichova2, Hana Rezackova2, Katerina Houfkova3, Radek Kucera2, Vaclava Cerna3, Tomas Kostlivy1, Ondrej Topolcan2, Martin Pesta3.   

Abstract

Background: Obstructive sleep apnea syndrome (OSAS) is one of the most common sleep-related breathing disorders. The aim of this study was to improve diagnostics in OSAS using blood circulating biomarkers. We consider the potential of cardiac-specific miRNAs in the diagnosis and risk assessment of cardiovascular complications. Materials & methods: Plasmatic levels of miR-1-3p, miR-133a-3p and miR-499a-5p were measured by reverse transcription-PCR and compared with the clinical status of OSAS patients and controls.
Results: The level of miR-499 was higher (p = 0.0343) in OSAS patients (mean expression: 0.00561) compared with the controls (mean expression: 0.00003), using the multivariate logistic regression.
Conclusion: The role of miR-499 in gene expression regulation during hypoxia and our findings indicate that miR-499 could be a new diagnostic biomarker for OSAS.

Entities:  

Keywords:  biomarker; cardiovascular disease; miR1; miR133a; miR499; miRNA; sleep apnea syndrome

Mesh:

Substances:

Year:  2021        PMID: 34289701     DOI: 10.2217/bmm-2020-0826

Source DB:  PubMed          Journal:  Biomark Med        ISSN: 1752-0363            Impact factor:   2.851


  2 in total

1.  Analysis of nocturnal, hypoxia-induced miRNAs in sleep apnea patients.

Authors:  Philip Roger Goody; Lisa Nachtsheim; Mohammed Rabiul Hosen; Miriam von Krosigk; Dominik Christmann; Jens Peter Klussmann; Andreas Zietzer; Nils Breitrück; Felix Jansen; Stefanie Jansen
Journal:  PLoS One       Date:  2022-03-04       Impact factor: 3.240

2.  miR-199a-5p Relieves Obstructive Sleep Apnea Syndrome-Related Hypertension by Targeting HIF-1α.

Authors:  Chunyan Guo; Minghui Zhang; Wei Su; Min Xu; Shumei Zhao
Journal:  J Immunol Res       Date:  2022-07-27       Impact factor: 4.493

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.